Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 96 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015', provides an overview of the Klebsiella Pneumoniae Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Klebsiella Pneumoniae Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Klebsiella Pneumoniae Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Klebsiella Pneumoniae Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Klebsiella Pneumoniae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Klebsiella Pneumoniae Infections Overview 10
Therapeutics Development 11
Pipeline Products for Klebsiella Pneumoniae Infections - Overview 11
Pipeline Products for Klebsiella Pneumoniae Infections - Comparative Analysis 12
Klebsiella Pneumoniae Infections - Therapeutics under Development by Companies 13
Klebsiella Pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes 15
Klebsiella Pneumoniae Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Klebsiella Pneumoniae Infections - Products under Development by Companies 18
Klebsiella Pneumoniae Infections - Products under Investigation by Universities/Institutes 21
Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development 22
Arsanis Biosciences GmbH 22
Cellceutix Corporation 23
Debiopharm International S.A. 24
Melinta Therapeutics, Inc 25
Merck & Co., Inc. 26
Northern Antibiotics Oy 27
Nosopharm SAS 28
Novan, Inc. 29
Pfizer Inc. 30
Phico Therapeutics Ltd. 31
Sarepta Therapeutics, Inc. 32
Shionogi & Co., Ltd. 33
Soligenix, Inc. 34
Sumitomo Dainippon Pharma Co., Ltd. 35
Syntiron LLC 36
Tetraphase Pharmaceuticals Inc. 37
Theraclone Sciences, Inc. 38
Trana Discovery, Inc. 39
Klebsiella Pneumoniae Infections - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BXN-112 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CB-027 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CB-618 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CC-1807 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CTIX-1278 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Debio-1454 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
dusquetide - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
IBN-1 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Klebsiella pneumoniae vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Monoclonal Antibodies for Klebsiella Pneumoniae Infections - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Monoclonal Antibody for Klebsiella Pneumoniae Infections - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
MVX-506 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NAB-7061 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
NAB-739 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NAB-741 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
NOSO-95300 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
NVN-1000 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NVN-4428 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
PT-4 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
RX-05 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
RXP-792 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RXP-873 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
S-649266 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SM-295291 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SM-369926 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
TP-076 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
TP-138 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
TP-600 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Klebsiella Pneumoniae Infections - Recent Pipeline Updates 87
Klebsiella Pneumoniae Infections - Dormant Projects 92
Klebsiella Pneumoniae Infections - Discontinued Products 93
Klebsiella Pneumoniae Infections - Product Development Milestones 94
Featured News & Press Releases 94
Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials 94
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012 94
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 95
Disclaimer 96

List of Tables

Number of Products under Development for Klebsiella Pneumoniae Infections, H1 2015 11
Number of Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Development by Companies, H1 2015 (Contd..2) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Klebsiella Pneumoniae Infections - Pipeline by Arsanis Biosciences GmbH, H1 2015 22
Klebsiella Pneumoniae Infections - Pipeline by Cellceutix Corporation, H1 2015 23
Klebsiella Pneumoniae Infections - Pipeline by Debiopharm International S.A., H1 2015 24
Klebsiella Pneumoniae Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015 25
Klebsiella Pneumoniae Infections - Pipeline by Merck & Co., Inc., H1 2015 26
Klebsiella Pneumoniae Infections - Pipeline by Northern Antibiotics Oy, H1 2015 27
Klebsiella Pneumoniae Infections - Pipeline by Nosopharm SAS, H1 2015 28
Klebsiella Pneumoniae Infections - Pipeline by Novan, Inc., H1 2015 29
Klebsiella Pneumoniae Infections - Pipeline by Pfizer Inc., H1 2015 30
Klebsiella Pneumoniae Infections - Pipeline by Phico Therapeutics Ltd., H1 2015 31
Klebsiella Pneumoniae Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2015 32
Klebsiella Pneumoniae Infections - Pipeline by Shionogi & Co., Ltd., H1 2015 33
Klebsiella Pneumoniae Infections - Pipeline by Soligenix, Inc., H1 2015 34
Klebsiella Pneumoniae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 35
Klebsiella Pneumoniae Infections - Pipeline by Syntiron LLC, H1 2015 36
Klebsiella Pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 37
Klebsiella Pneumoniae Infections - Pipeline by Theraclone Sciences, Inc., H1 2015 38
Klebsiella Pneumoniae Infections - Pipeline by Trana Discovery, Inc., H1 2015 39
Assessment by Monotherapy Products, H1 2015 40
Number of Products by Stage and Target, H1 2015 42
Number of Products by Stage and Mechanism of Action, H1 2015 44
Number of Products by Stage and Route of Administration, H1 2015 46
Number of Products by Stage and Molecule Type, H1 2015 48
Klebsiella Pneumoniae Infections Therapeutics - Recent Pipeline Updates, H1 2015 87
Klebsiella Pneumoniae Infections - Dormant Projects, H1 2015 92
Klebsiella Pneumoniae Infections - Discontinued Products, H1 2015 93